Last updated: March 14, 2026
What is the scope of patent JP7301918?
Patent JP7301918, filed by a Japanese pharmaceutical company, covers a novel compound designed for the treatment of specific diseases, notably cancers. The patent's claims broadly encompass the compound's structure, derivatives, and methods of use, including specific methods of synthesis and pharmaceutical formulations.
The patent claims are divided into three core categories:
- Compound claims: Covering the chemical structure of the compound itself, including various derivatives within defined structural boundaries.
- Method claims: Covering processes for synthesizing the compound.
- Use claims: Covering therapeutic applications, notably treating cancer or related diseases.
The chemical structure is based on a heterocyclic framework with substitutions that confer specific biological activities. The patent explicitly claims derivatives with substitutions at key positions, extending the scope to closely related compounds.
Key structural features claimed:
- A core heterocyclic scaffold.
- Specific substitutions at designated positions.
- Pharmacologically active derivatives.
The claims are designed to provide protection not only for the disclosed compound but also for derivatives with minor modifications, reducing the risk of workarounds.
What are the core claims?
Claim 1 (Main compound claim)
The primary claim covers a compound defined by a specific chemical formula, with variations allowed via substitutions at certain positions. This claim aims to monopolize the core chemical scaffold and its most promising derivatives.
Claim 2-10 (Dependent claims)
These specify variations of the compound with different substituents that impact solubility, bioavailability, or activity. They also include specific stereochemistry embodiments.
Claim 11-15 (Method of synthesis)
Describe a process for preparing the compound, focusing on key reaction steps such as coupling or substitution reactions.
Claim 16-20 (Therapeutic use)
Claims the use of the compound or derivatives in treating cancers, specifically by inhibiting certain molecular pathways, such as tyrosine kinase activity.
Patent landscape overview and landscape position
Patent family and related patents
- The applicant has filed multiple family members internationally, including in the US, Europe, and China, indicating strong global patent protection intent.
- The patent family includes filings with similar claims targeting broad classes of derivatives.
Priority and filing dates
- Priority date: December 28, 2020.
- Publication date: August 25, 2022.
Related patent filings
- Similar patents focus on structural modifications and specific therapeutic indications.
- Patent filings targeting different disease states or similar compounds with known modifications.
Competitor patents
- Several patents filed by competitors target similar heterocyclic compounds or mechanisms, particularly kinase inhibitors.
- These patents generally focus on specific substituents or methods, with overlapping claims to core structures.
Patent landscape challenges
- The landscape contains patents with overlapping structural claims, requiring careful or narrow claim drafting for freedom to operate.
- The presence of prior art involving heterocyclic scaffolds suggests that secondary considerations and method claims will be critical for enforceability.
Patent protection and potential issues
- The broad structural claims provide extensive protection for derivatives, but their enforceability depends on precise claim interpretation and validity assessments.
- Therapeutic use claims are narrower; their strength depends on supporting data and patentable inventive step.
- Patent challenges could arise from similar compounds claimed in earlier patents, primarily from research on kinase inhibitors and heterocyclic drugs in oncology.
Policy and legal considerations
- Japanese patent law allows broad compound and use claims if they meet inventive step and industrial applicability criteria.
- The patent's scope will be tested in opposition or invalidation proceedings, especially for broad compound claims.
Key insights:
- JP7301918 offers robust protection over the core chemical structure and manufacturing methods.
- Patent landscape indicates growing competition in kinase inhibitor space, emphasizing the importance of strategic claim drafting.
- The therapeutic method claims are narrower but can serve as enforceable barriers once clinical efficacy is demonstrated.
- International patent filings complement the Japanese patent, creating a multi-jurisdictional barrier to market entry.
Key Takeaways
- JP7301918 claims a heterocyclic compound with derivatives for cancer therapy.
- Its scope focuses on the compound, synthesis methods, and therapeutic applications, with broad derivative coverage.
- The patent landscape features overlapping patents in kinase inhibitors, requiring careful navigation.
- Strengths include extensive structural claims and international filings; weaknesses involve potential prior art overlaps.
- The patent provides a foundation for aggressive R&D and licensing strategies in targeted cancer therapies.
5 FAQs
- Can the scope of JP7301918 be challenged based on prior art? Yes. Overlaps with existing kinase inhibitor patents may lead to validity challenges, especially if similar heterocyclic scaffolds are disclosed.
- What are the key elements for designing around JP7301918? Focus on structural modifications at unclaimed positions or developing alternative synthetic pathways that fall outside the patent claims.
- How does the patent protect method of use claims? The claims protect specific therapeutic applications, provided the patent discloses sufficient data supporting these uses and meets inventive step requirements.
- What is the importance of international filings? They extend patent protection beyond Japan, enabling global market access and blocking competitors in major jurisdictions.
- How might competitors design around this patent? By developing structurally distinct compounds outside of the specified heterocyclic framework or different mechanisms of action.
References
[1] Japan Patent Office. (2022). Patent JP7301918. Retrieved from Japan Patent Office database.
[2] PatentScope. (2022). Worldwide patent filings related to kinase inhibitors. Retrieved from WIPO database.
[3] European Patent Office. (2022). Patent family analysis related to heterocyclic compounds. Retrieved from EPO database.
[4] Smith, J. (2023). Patent strategies in kinase inhibitor development. Journal of Patent Law, 45(2), 134-148.
[5] World Intellectual Property Organization. (2022). Patent landscape report on targeted cancer therapies. Retrieved from WIPO publications.
